PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Collaborations Pharmaceuticals, 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA. Electronic address: sean@collaborationspharma.com.\', \'LabMol - Laboratory of Molecular Modeling and Drug Design, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, GO 74605-170, Brazil.\', \'Collaborations Pharmaceuticals, 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.\', \'InsilicAll, São Paulo, SP 04363-090, Brazil.\', \'Division of Infectious Diseases and Immunology, Department of Medicine, New York University, NY, USA; Department of Population and Family Health, Mailman School of Public Health, Columbia University, NY, USA.\', \'TW2Informatics Ltd, Göteborg 42166, Sweden.\', \'LabMol - Laboratory of Molecular Modeling and Drug Design, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, GO 74605-170, Brazil; Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, SP 13083-864, Brazil. Electronic address: carolina@ufg.br.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1359-6446(20)30145-810.1016/j.drudis.2020.03.019
?:doi
?:hasPublicationType
?:journal
  • Drug discovery today
is ?:pmid of
?:pmid
?:pmid
  • 32320852
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.008
?:rankingScore_hIndex
  • 150
?:title
  • Déjà vu: Stimulating open drug discovery for SARS-CoV-2.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32320852>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32320852>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all